Penn emerges from Novartis alliance a prolific source of cell, gene therapies

University of Pennsylvania is closing out its seven year landmark CAR T partnership with Novartis with a stable of collaborations and a list of new directions for CARs, both in and out of cancer.

Penn’s 2012 deal with Novartis AG (NYSE:NVS; SIX:NOVN) led to the first approved chimeric antigen receptor (CAR) T cell

Read the full 523 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE